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The main objective of the present study is to develop a self-
micellizing solid dispersion (SMSD) system of cyclosporine A
(CsA) using an amphiphilic copolymer, poly[MPC-co-BMA] (pMB)
to improve the biopharmaceutical properties of CsA (Fig. 1A).
Unlike conventional carrier compounds, pMB would perform
the bifunctional ability as both polymeric carrier of solid dis-
persion system and solubilizer derived from a high micellizing
property, which could be considered beneficial for the produc-
tion of highly water soluble formulation of poorly water soluble
compound [1]. Improvement in the aqueous solubility has been
believed to be a key consideration for acquiring potent phar-
macological effects of BCS class II drug like CsA. However, far
less is known about its feasibility and applicability of pMB to
solid dispersion systems and CsA with its high molecular
weight.
pMB-based solid dispersion of CsA with drug loading 15%
(w/w) was prepared using a wet-milling system, and its
physicochemical properties were characterized with respect
to the morphology, particle size distribution, dissolution be-
havior, crystallinity and stability. Pharmacokinetic studies of
orally dosed CsA formulations were also performed to assess
the improvement of oral absorption in rats. The cytotoxicity
of pMB was assessed in rat intestinal IEC-6 cells, and the
pMB was less cytotoxic than polysorbate 80, a non-ionic
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surfactant with a wide safety margin. The SMSD/CsA exhib-
ited immediate formation of fine micelles with a mean
diameter of ca. 180 nm when introduced into aqueous media.
There was marked improvement in the dissolution behavior
of the SMSD/CsA compared with amorphous CsA. Even after
storage at 40 °C/75% relative humidity, the dissolution behav-
ior of aged SMSD/CsA seemed to be almost identical to that
of its freshly prepared equivalent, and CsA in aged SMSD/
CsA was still in amorphous form. After oral administration
of SMSD/CsA (10 mg CsA/kg) in rats, enhanced CsA exposure
was observed with increases of Cmax and bioavailability by ca.
11- and 42-fold, respectively, compared with those of amor-
phous CsA (Fig. 1B). From these findings, the pMB-based
SMSD system might be an efficacious approach for improve-
ments in oral bioavailability of CsA.
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Fig. 1 – The schematic image (A) and pharmacokinetic study after oral administration (B) of SMSD/CsA.
51a s i an j o u rna l o f p h a rma c eu t i c a l s c i e n c e s 1 1 ( 2 0 1 6 ) 5 0 – 5 1
